Recruiting
Phase 3

Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

Sponsor:

Vertex Pharmaceuticals Incorporated

Code:

NCT05422222

Conditions

Cystic Fibrosis

Eligibility Criteria

Sex: All

Age: 1 - 11

Healthy Volunteers: Not accepted

Interventions

VX-121/TEZ/D-IVA

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information